Cargando…
Combination antiretroviral therapy (cART) restores HIV-1 infection-mediated impairment of JAK-STAT signaling pathway
JAK-STAT signaling pathway has a crucial role in host innate immunity against viral infections, including HIV-1. We therefore examined the impact of HIV-1 infection and combination antiretroviral therapy (cART) on JAK-STAT signaling pathway. Compared to age-matched healthy donors (n = 18), HIV-1-inf...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5410242/ https://www.ncbi.nlm.nih.gov/pubmed/28186978 http://dx.doi.org/10.18632/oncotarget.15121 |
_version_ | 1783232635523301376 |
---|---|
author | Liu, Man-Qing Zhao, Min Kong, Wen-Hua Tang, Li Wang, Fang Zhu, Ze-Rong Wang, Xia Qiu, Hong-Yan Zhou, Dun-Jin Wang, Xu Ho, Wen-Zhe Zhou, Wang |
author_facet | Liu, Man-Qing Zhao, Min Kong, Wen-Hua Tang, Li Wang, Fang Zhu, Ze-Rong Wang, Xia Qiu, Hong-Yan Zhou, Dun-Jin Wang, Xu Ho, Wen-Zhe Zhou, Wang |
author_sort | Liu, Man-Qing |
collection | PubMed |
description | JAK-STAT signaling pathway has a crucial role in host innate immunity against viral infections, including HIV-1. We therefore examined the impact of HIV-1 infection and combination antiretroviral therapy (cART) on JAK-STAT signaling pathway. Compared to age-matched healthy donors (n = 18), HIV-1-infected subjects (n = 18) prior to cART had significantly lower expression of toll-like receptors (TLR-1/4/6/7/8/9), the IFN regulatory factors (IRF-3/7/9), and the antiviral factors (OAS-1, MxA, A3G, PKR, and Tetherin). Three months’ cART partially restores the impaired functions of JAK-STAT-mediated antiviral immunity. We also found most factors had significantly positive correlations (p < 0.05) between each two factors in JAK-STAT pathway in healthy donors (98.25%, 168/171), but such significant positive associations were only found in small part of HIV-1-infected subjects (43.86%, 75/171), and stably increased during the cART (57.31%, 98/171 after 6 months’ cART). With regard to the restoration of some HIV-1 restriction factors, HIV-1-infected subjects who had CD4+ T cell counts > 350//μl responded better to cART than those with the counts < 350/μl. These findings indicate that the impairment of JAK-STAT pathway may play a role in the immunopathogenesis of HIV-1 disease. |
format | Online Article Text |
id | pubmed-5410242 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-54102422017-05-04 Combination antiretroviral therapy (cART) restores HIV-1 infection-mediated impairment of JAK-STAT signaling pathway Liu, Man-Qing Zhao, Min Kong, Wen-Hua Tang, Li Wang, Fang Zhu, Ze-Rong Wang, Xia Qiu, Hong-Yan Zhou, Dun-Jin Wang, Xu Ho, Wen-Zhe Zhou, Wang Oncotarget Research Paper JAK-STAT signaling pathway has a crucial role in host innate immunity against viral infections, including HIV-1. We therefore examined the impact of HIV-1 infection and combination antiretroviral therapy (cART) on JAK-STAT signaling pathway. Compared to age-matched healthy donors (n = 18), HIV-1-infected subjects (n = 18) prior to cART had significantly lower expression of toll-like receptors (TLR-1/4/6/7/8/9), the IFN regulatory factors (IRF-3/7/9), and the antiviral factors (OAS-1, MxA, A3G, PKR, and Tetherin). Three months’ cART partially restores the impaired functions of JAK-STAT-mediated antiviral immunity. We also found most factors had significantly positive correlations (p < 0.05) between each two factors in JAK-STAT pathway in healthy donors (98.25%, 168/171), but such significant positive associations were only found in small part of HIV-1-infected subjects (43.86%, 75/171), and stably increased during the cART (57.31%, 98/171 after 6 months’ cART). With regard to the restoration of some HIV-1 restriction factors, HIV-1-infected subjects who had CD4+ T cell counts > 350//μl responded better to cART than those with the counts < 350/μl. These findings indicate that the impairment of JAK-STAT pathway may play a role in the immunopathogenesis of HIV-1 disease. Impact Journals LLC 2017-02-06 /pmc/articles/PMC5410242/ /pubmed/28186978 http://dx.doi.org/10.18632/oncotarget.15121 Text en Copyright: © 2017 Liu et al. http://creativecommons.org/licenses/by/3.0/ This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) (CC-BY), which permits unrestricted use and redistribution provided that the original author and source are credited. |
spellingShingle | Research Paper Liu, Man-Qing Zhao, Min Kong, Wen-Hua Tang, Li Wang, Fang Zhu, Ze-Rong Wang, Xia Qiu, Hong-Yan Zhou, Dun-Jin Wang, Xu Ho, Wen-Zhe Zhou, Wang Combination antiretroviral therapy (cART) restores HIV-1 infection-mediated impairment of JAK-STAT signaling pathway |
title | Combination antiretroviral therapy (cART) restores HIV-1 infection-mediated impairment of JAK-STAT signaling pathway |
title_full | Combination antiretroviral therapy (cART) restores HIV-1 infection-mediated impairment of JAK-STAT signaling pathway |
title_fullStr | Combination antiretroviral therapy (cART) restores HIV-1 infection-mediated impairment of JAK-STAT signaling pathway |
title_full_unstemmed | Combination antiretroviral therapy (cART) restores HIV-1 infection-mediated impairment of JAK-STAT signaling pathway |
title_short | Combination antiretroviral therapy (cART) restores HIV-1 infection-mediated impairment of JAK-STAT signaling pathway |
title_sort | combination antiretroviral therapy (cart) restores hiv-1 infection-mediated impairment of jak-stat signaling pathway |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5410242/ https://www.ncbi.nlm.nih.gov/pubmed/28186978 http://dx.doi.org/10.18632/oncotarget.15121 |
work_keys_str_mv | AT liumanqing combinationantiretroviraltherapycartrestoreshiv1infectionmediatedimpairmentofjakstatsignalingpathway AT zhaomin combinationantiretroviraltherapycartrestoreshiv1infectionmediatedimpairmentofjakstatsignalingpathway AT kongwenhua combinationantiretroviraltherapycartrestoreshiv1infectionmediatedimpairmentofjakstatsignalingpathway AT tangli combinationantiretroviraltherapycartrestoreshiv1infectionmediatedimpairmentofjakstatsignalingpathway AT wangfang combinationantiretroviraltherapycartrestoreshiv1infectionmediatedimpairmentofjakstatsignalingpathway AT zhuzerong combinationantiretroviraltherapycartrestoreshiv1infectionmediatedimpairmentofjakstatsignalingpathway AT wangxia combinationantiretroviraltherapycartrestoreshiv1infectionmediatedimpairmentofjakstatsignalingpathway AT qiuhongyan combinationantiretroviraltherapycartrestoreshiv1infectionmediatedimpairmentofjakstatsignalingpathway AT zhoudunjin combinationantiretroviraltherapycartrestoreshiv1infectionmediatedimpairmentofjakstatsignalingpathway AT wangxu combinationantiretroviraltherapycartrestoreshiv1infectionmediatedimpairmentofjakstatsignalingpathway AT howenzhe combinationantiretroviraltherapycartrestoreshiv1infectionmediatedimpairmentofjakstatsignalingpathway AT zhouwang combinationantiretroviraltherapycartrestoreshiv1infectionmediatedimpairmentofjakstatsignalingpathway |